HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, X. C. Articles by Strom, T. B. Search for Related Content PubMed PubMed Citation Articles by Li, X. C. Articles by Strom, T. B.

Induction of Allograft Tolerance in the Absence of Fas-Mediated Apoptosis¹

Xian Chang Li^2,*, Yongsheng Li^2,*, Ingrid Dodge^*, Andrew D. Wells, Xin Xiao Zheng^*, Laurence A. Turka and Terry B. Strom^3,*

^* Department of Medicine, Harvard Medical School, Division of Immunology, Beth Israel Deaconess Medical Center, Boston, MA 02215; and Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Using certain immunosuppressive regimens, IL-2 knockout (KO) mice, in contrast to wild-type (wt) controls, are resistant to the induction of allograft tolerance. The mechanism by which IL-2 regulates allograft tolerance is uncertain. As IL-2 KO mice have a profound defect in Fas-mediated apoptosis, we hypothesized that Fas-mediated apoptosis of alloreactive T cells may be critical in the acquisition of allograft tolerance. To definitively study the role of Fas in the induction of transplantation tolerance, we used Fas mutant B6.MRL-lpr mice as allograft recipients of islet and vascularized cardiac transplants. Alloantigen-stimulated proliferation and apoptosis of Fas-deficient cells were also studied in vivo. Fas mutant B6.MRL-lpr (H-2^b) mice rapidly rejected fully MHC-mismatched DBA/2 (H-2^d) islet allografts and vascularized cardiac allografts with a tempo that is comparable to wt control mice. Both wt and B6.MRL-lpr mice transplanted with fully MHC-mismatched islet allografts or cardiac allografts can be readily tolerized by either rapamycin or combined costimulation blockade (CTLA-4Ig plus anti-CD40L mAb). Despite the profound defect of Fas-mediated apoptosis, Fas-deficient T cells can still undergo apoptotic cell death in vivo in response to alloantigen stimulation. Our study suggests that: 1) Fas is not necessarily essential for allograft tolerance, and 2) Fas-mediated apoptosis is not central to the IL-2-dependent mechanism governing the acquisition of allograft tolerance.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Tolerance to self Ags is established primarily in the thymus by deletion of autoreactive T cells through negative selection (1, 2). Similarly, tolerance to fully MHC-mismatched allografts and even xenografts can be achieved by creation of mixed hematopoietic chimerism, where deletion of donor-specific alloreactive T cells in the thymus is a principle mechanism through which tolerance is induced (3). Thus, it is generally believed that deletional mechanisms leading to allograft tolerance provide the most robust form of tolerance in transplantation. Is a deletional process involved in the establishment of peripheral allograft tolerance in the absence of immune system ablation and reconstitution? The answer remains enigmatic.

Recently, we have used rapamycin and others used costimulation blockade treatment to demonstrate that IL-2 is not required for rejection (4). In fact, IL-2 can be required for tolerance induction (5, 6). The precise mechanisms by which IL-2 regulates tolerance induction remain unknown. T cells in wild-type (wt)⁴ and IL-2 knockout (KO) mice express comparable levels of CTLA-4 upon activation (our unpublished observations), which has been shown to be critical for induction of peripheral tolerance (7). In stark contrast to wt mice, IL-2 KO mice exhibit a profound defect in Fas-mediated apoptosis, despite normal expression of Fas upon T cell activation (8). As IL-2 is absolutely required for priming activated T cells to undergo Fas-mediated apoptosis (9), it has been suggested that the failure of tolerance induction in IL-2 KO mice may be due to impaired Fas-mediated deletion of activated alloreactive T cells. This hypothesis is reinforced by the finding that cotransplantation of syngeneic myoblasts genetically engineered to express Fas ligand with islets allograft leads to long-term allograft survival, and T cell apoptosis induced by the Fas ligand-expressing myoblasts is the principle mechanism of long-term engraftment (10). Moreover, systemic administration of macrophages genetically constructed to express high levels of Fas ligand into allogeneic recipients promotes rapid apoptosis of alloreactive T cells, leading to Ag-specific T cell tolerance (11). George et al. (12) recently demonstrated, in a bone marrow-induced skin allograft tolerance model, that: 1) expression of Fas ligand by donor bone marrow cells is critical for tolerance induction; and 2) apoptosis of alloreactive T cells is essential in the establishment of tolerant status in this model.

To definitively study whether Fas expression is an absolute requirement for the induction and maintenance of IL-2-dependent allograft tolerance that occurs with rapamycin or costimulation treatment, we studied the allograft response in Fas mutant B6.MRL-lpr mice as transplant recipients. We also investigated the alloantigen-driven T cell proliferation and activation-induced cell death (AICD) in vivo. We found that: 1) allograft tolerance can be induced in the absence of Fas expression, 2) alloantigen-activated and Fas-deficient T cells can still undergo apoptotic cell death in vivo, and 3) Fas-mediated apoptosis is not central to IL-2-dependent acquisition of allograft tolerance.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Animals

Eight- to ten-week-old male DBA/2 (H-2^d) mice, B6.MRL^+/+ wt (H-2^b), and Fas mutant B6.MRL-lpr/lpr mice (H-2^b) were obtained from the Jackson Laboratory (Bar Harbor, ME).

Islet cell transplantation

Islet transplantation was performed as described previously (13). Briefly, pancreatic islets were isolated from donor DBA/2 (H-2^d) mice via collagenase digestion and subsequent ficoll gradient centrifugation method. Crude islets 300–400(300–400) were transplanted under the renal capsule into wt mice (H-2^b) and Fas mutant B6.MRL-lpr mice (H-2^b) rendered diabetic by a single i.p. injection of streptozotocin (225 mg/kg; Sigma, St. Louis, MO). Allograft function was monitored by sequential blood glucose measurements. Primary graft function was defined as blood glucose levels under 200 mg/dl on day 3 posttransplantation, and graft rejection was defined as a rise in blood glucose levels exceeding 300 mg/dl following a period of primary graft function.

Vascularized heterotopic cardiac transplantation

Heterotopic cardiac transplantation was performed (14). Briefly, cardiac grafts from DBA/2 donors were prepared by ligating the pulmonary veins and the superior vena cava. The grafts were harvested by dividing and excising the aorta and the pulmonary artery. The cardiac grafts were then transplanted into recipient mice by suturing donor aorta and donor pulmonary artery end to side to the recipient’s abdominal aorta and vena cava, respectively. Graft function was monitored every other day following transplantation by transabdominal palpation and scored on a scale of 1 to 4, based on the strength and the rate of impulses. Graft rejection was defined by a complete cessation of palpable beat and confirmed by direct visualization upon laprotomy.

Reagents and tolerizing protocols

Rapamycin was kindly provided by Dr. Suren Sehgal (Wyeth-Ayerst, Princeton, NJ) and prepared in carboxymethylcellulose (Sigma), as recommended by the company. Murine CTLA-4Ig was constructed and expressed in our laboratory as previously described (15). A B cell hybridoma producing MR1 (IgG2a) hamster anti-mouse CD40L mAb was obtained from American Type Culture Collection (Manassas, VA). The hybridoma cells were grown in serum free UltraCulture medium (BioWhittaker, Walkersville, MD). MR1 mAb was purified using protein G columns (Sigma).

Treatment with rapamycin consisted of 0.2 mg/kg/day i.p. for the first 3 days after transplantation, followed by every other day for 14 days. Combined costimulation blockade treatment consisted of CTLA-4Ig at 0.25 mg i.p. on posttransplant day 2 and anti-CD40L mAb at 0.2 mg i.p. on posttransplant days 0, 2, and 4.

Analysis of Fas expression

Splenic leukocytes were prepared from wt control mice and Fas mutant B6.MRL-lpr mice. In some experiments, cells were activated with anti-CD3 (2 µg/ml, 145-2C11; PharMingen, San Diego, CA) in vitro for 3 days. Cells were stained with a PE-conjugated anti-mouse Fas Ab (Jo-2, PharMingen) on ice for 20 min, followed by washing the cells twice in PBS/0.5% BSA. An isotype-matched hamster IgG2a (PharMingen) was used in the staining as a control. Cell were then analyzed with FACSort (Becton Dickinson, Mountain View, CA). Results are presented in histograms.

Analysis of AICD

AICD in vitro was analyzed by annexin V staining (16). Briefly, splenic leukocytes (2 x 10⁶/ml) prepared from wt and Fas mutant B6.MRL-lpr mice were activated with anti-CD3 (2 µg/ml, 145-2C11; PharMingen) in vitro for 3 days. Viable T cell blasts were isolated using Lympholyte-M medium (Cedarlane, Ontario, Canada) and then cultured on anti-Fas (Jo-2; PharMingen)-coated plates for 8 h. Cells cultured on control hamster IgG-coated plates were used as a control. Cells were harvested, stained with PE-conjugated annexin V (PharMingen) on ice for 15 min, and analyzed by FACSort (Becton Dickinson).

Tracking of 5-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled lymphocytes in vivo

Spleens and lymph nodes from wt and B6.MRL-lpr mice were harvested and single cell suspension prepared in HBSS by gently pressing the tissue through a fine metal mesh. RBC were lysed by hypotonic shock. Lymphocytes were washed and resuspended in serum-free HBSS at 1 x 10⁷/ml for labeling with a tracking fluorochrome CFSE (CFDASE; Molecular Probes, Portland, OR), as previously described (17, 18). Briefly, CFDASE was dissolved in DMSO, and an aliquot was added into the cell suspension at a final concentration of 5 µM. Cells were incubated at room temperature for 6 min, and the labeling was terminated by the addition of one-tenth of the volume of FCS. Cells were then washed twice in cold RPMI 1640 medium supplemented with 10% FCS and resuspended in HBSS for i.v. injection.

CFDASE is a lipophilic chemical that can passively diffuse into the plasma membrane of living cells, where it is converted to a green fluorochrome CFSE by esterase hydrolysis. CFSE forms stable complex with cellular proteins and cannot diffuse out of the cells. As cells divide, CFSE segregates equally between two daughter cells. Thus, the fluorescent intensity of CFSE halves consecutively with each cell division, allowing precise monitoring of the mitotic activity of cells in vivo (17, 18).

DBA/2 mice were lethally irradiated (1000 rad) with a GammaCell (Ontario, Canada) irradiator immediately before i.v. injection of CFSE-labeled lymphocytes. Each mouse then received 4–6 x 10⁷ labeled cells via the penile vein. Mice were sacrificed 2–3 days after i.v. injection of labeled lymphocytes, spleens were harvested from host mice, and a single cell suspension was prepared. The cellular pattern of proliferation in vivo, as reflected by distinct CFSE profile, was analyzed by flow cytometry. Data were collected and analyzed by gating onto the CFSE-positive cells.

Analysis of cell divisions and apoptosis of alloreactive T cells in vivo

CFSE-labeled cells (4–6 x 10⁷/mouse) from wt and B6.MRL-lpr mice were injected i.v. into lethally irradiated DBA/2 hosts. Splenic leukocytes from the host mice were prepared 2 days later. Cells were stained with a biotinylated anti-mouse CD4 mAb (GK1.5; PharMingen) on ice for 20 min, followed by staining with streptavidin-CyChrome (PharMingen) and PE-conjugated annexin V on ice for 15 min. Cells were washed twice in annexin labeling buffer. Proliferation and apoptotic cell death of CD4⁺ T cells in each distinct cell division were analyzed by flow cytometry. Data were collected and analyzed by gating onto CD4⁺CFSE⁺ cells.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
To study the allograft response in the absence of Fas expression, we transplanted fully MHC-mismatched DBA/2 (H-2^d) islet allografts into Fas mutant B6.MRL-lpr (H-2^b) mice and compared the rejection with that of wt control (H-2^b) recipients. As shown in Table I, wt control mice rejected DBA/2 islet allografts with a mean survival time (MST) of 13 days (n = 5), and Fas mutant B6.MRL-lpr mice rejected the DBA/2 islet allografts with an MST of 11 days (n = 7). Histological examination of rejecting islet allografts in B6.MRL-lpr mice on posttransplant day 8 revealed dense mononuclear infiltration, which was essentially identical to that observed in wt control recipients (data not shown). Thus, expression of Fas by transplant recipients is not required for the execution of allograft rejection.

Nephrectomy of the left kidney (the islet allografts were placed under the renal capsule) in three B6.MRL-lpr recipients 100 days after transplantation led to a sharp rise in the blood glucose levels, demonstrating that euglycemia was maintained by the islet allografts. Each of the three nephrectomized mice accepted a second DBA/2 islet allograft without any immunosuppression (Fig. 1), indicating a state of stable allograft tolerance.

View larger version (18K): [in this window] [in a new window]   FIGURE 1. Induction of allograft tolerance in rapamycin-treated B6.MRL-lpr recipients. Nephrectomy of the islet graft-bearing kidney in three B6.MRL-lpr recipients 100 days after transplantation led to a sharp rise of blood glucose levels. Each of the three nephrectomized recipient mice accepted a second DBA/2 islet allograft without any immunosuppression.

To prove that tolerance induction in Fas mutant B6.MRL-lpr mice is not restricted to the islet allografts, vascularized DBA/2 (H-2^d) cardiac allografts were transplanted into Fas mutant B6.MRL-lpr mice (H-2^b) and treated with rapamycin. As shown in Table II, untreated B6.MRL-lpr mice rejected the DBA/2 cardiac allografts with a MST of 13 days (n = 3) with no marked difference, compared with wt control mice (MST = 13 days, n = 3). Similar to our finding in the islet model, treatment with rapamycin produced long-term cardiac allograft survival in both wt and Fas mutant B6.MRL-lpr recipient mice (MST > 100 days, n = 3–5).

View larger version (17K): [in this window] [in a new window]   FIGURE 2. Expression of Fas by splenic leukocytes from wt control mice and Fas mutant B6.MRL-lpr mice analyzed by FACS. A, Resting splenic leukocytes. B, Anti-CD3-activated splenic leukocytes.

View larger version (28K): [in this window] [in a new window]   FIGURE 3. Fas-mediated apoptosis of activated T cells in vitro. Splenic leukocytes from wt and Fas mutant B6.MRL-lpr mice were stimulated with anti-CD3 (2C11, 2 µg/ml) for 3 days. Activated T cells were isolated and further cultured on anti-Fas-coated plates (Jo-2, 2 µg/ml) for 8 h. Apoptotic cell death was analyzed by annexin V staining. Cells cultured on control hamster IgG were included as a control.

View larger version (13K): [in this window] [in a new window]   FIGURE 4. IL-2/Fc failed to provoke cardiac allograft rejection in rapamycin-tolerized Fas mutant lpr recipients. IL-2/Fc was given i.p. at 5 µg/daily for 10 days starting on posttransplant day 100.

View larger version (23K): [in this window] [in a new window]   FIGURE 5. Analysis of donor-specific alloreactive lymphocytes in vivo in tolerized B6.MRL-lpr recipient mice. Splenocytes from control B6.MRL-lpr mice and rapamycin-tolerized B6.MRL-lpr mice were labeled with CFSE and injected into irradiated DBA/2 hosts. Cell proliferation was analyzed by the fluorescent profiles of CFSE-labeled cells.

View larger version (27K): [in this window] [in a new window]   FIGURE 6. Proliferation and apoptosis of Fas-deficient T cells in vivo in response to alloantigen. Splenic lymphocytes from B6.MRL-lpr mice were labeled with CFSE and injected i.v. into irradiated DBA/2 hosts. Two days later, spleens from DBA/2 hosts were harvested and single cell suspension prepared. Cells were then stained with CyChrome-anti-CD4 and PE-annexin V. Proliferation and apoptosis of CFSE-labeled CD4+ T cells among distinct generations were analyzed by flow cytometry. Representative data of five experiments are shown.

View larger version (28K): [in this window] [in a new window]   FIGURE 7. Proliferation and apoptosis of wt T cells in vivo in response to alloantigen. Splenic lymphocytes from wt control mice were labeled with CFSE and injected i.v. into irradiated DBA/2 hosts. Two days later, spleens from DBA/2 hosts were harvested and single cell suspension prepared. Cells were then stained with CyChrome-anti-CD4 and PE-annexin V. Proliferation and apoptosis of CFSE-labeled CD4+ T cells among distinct generations were analyzed by flow cytometry. Representative data of three experiments are shown.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Since the elucidation of a critical role of Fas/Fas ligand in conferring the immune privilege in the anterior chamber of the eyes and the testis (25, 26), there has been great interest in constructing Fas ligand-expressing allografts as a mean to promote allograft tolerance by killing graft-infiltrating Fas-positive T cells. Clearly, high levels of Fas ligand expression by the parenchymal cells of the testis and anterior chamber of the eyes are required for conferring the immune privileged status of these organs (25, 26). Elegant studies using Fas mutant and Fas ligand mutant mice have also demonstrated that transplantation of allogeneic, or even xenogeneic, tissues that express high levels of Fas ligand into the testis or the anterior chamber of the eye prevented rejection of these tissues, while tissues from Fas ligand mutant mice were rapidly rejected (25). While Fas/Fas ligand interaction is clearly critical in the tolerant status in some situations, our study suggests that expression of Fas by recipient lymphocytes is not a prerequisite for the induction and maintenance of peripheral allograft tolerance. Yet, Fas/Fas ligand interactions play a minimal role in preventing allograft rejection outside of the immune-privileged sites (27). Apparently, the unique local microenvironment of immune-privileged sites, aside from the expression of Fas ligand, must also play an active role in conferring the tolerant status. Indeed, induction of Ag-specific tolerance in the privileged sites is often associated with production of high levels of immunoregulatory cytokines, such as TGF-ß (28). Thus, the mechanisms underlying immune privilege and the role of Fas/Fas ligand in the induction of tolerant status other than the privileged sites warrant further study.

Another key finding of our study is that the Fas-mediated apoptosis is not central to the IL-2-dependent mechanisms governing the acquisition of allograft tolerance. Interestingly, the phenotype of Fas mutant B6.MRL-lpr mice and IL-2 KO mice share several common attributes. Both strains of mice develop lymphoproliferative disorders, autoimmunity, and accumulation of T cells with activated phenotype in the periphery (24, 29). The critical role of IL-2 for the functional integrity of Fas is further underscored by the finding that Fas-triggered apoptosis of activated T cells requires active IL-2 priming (9). Although the precise mechanism by which IL-2 regulates Fas-mediated AICD remains to be firmly defined, a recent study suggested that IL-2 can down-regulate the expression of cellular Fas-associated death domain-like IL-1-converting enzyme (FLICE) inhibitory protein (FLIP) (30). Structurally, FLIP has two death effector domains (DED) and a caspase 8-like domain (31). FLIP can dimerize with Fas-associated death domain protein (FADD) and/or caspase 8 via DED-DED interaction, which prevents the recruitment of death effector caspases down stream of FADD (31). Thus, in the absence of IL-2, FLIP is believed to be expressed at high levels, and therefore, FADD cannot recruit key caspases to execute AICD upon ligand binding (30, 31). Despite the intimate association of IL-2 with the functional integrity of Fas, it is fascinating that allograft tolerance can be readily induced in Fas mutant B6.MRL-lpr mice, whereas IL-2 KO mice are totally resistant to the induction of allograft tolerance (5, 6). This finding raises intriguing questions about the precise nature of IL-2-dependent processes that govern the acquisition of peripheral allograft tolerance.

We still favor the possibility that IL-2-regulated apoptotic events may be required for the acquisition of peripheral allograft tolerance. It has been shown that delivery of IL-2 into Fas mutant lpr mice through a recombinant viral vector can induce deletion of autoreactive T cells and remission from autoimmunity (32). In the present study, we also clearly show that Fas-deficient lymphocytes can still undergo AICD in vivo in response to alloantigen stimulation, and this type of AICD appears to be cell cycle-dependent (Fig. 6). IL-2-regulated AICD, a critical component of immune regulation, is not confined to the Fas pathway. The Fas/Fas ligand interaction is a part, but certainly not the entirety, of this network. For example, IL-2 KO mice have a defect in superantigen-triggered AICD that is Fas-independent (our unpublished observation). Although defects in Fas or Fas ligand are permissive for autoimmunity, most Fas- or Fas ligand-defective mouse strains do not suffer from overt autoimmunity. Our study further illustrates the limitations of Fas/Fas ligand-triggered apoptosis in determining peripheral allograft tolerance, as defective expression of Fas did not lead to a precipitous decline in AICD or inability to tolerance induction. Clearly, IL-2 influences multiple aspects of T cell apoptosis. The apoptotic pathways are extremely redundant and complex, at least five distinct death receptors have been identified (Fas, TNF receptor type I, DR3, DR4, and DR5), and each can mediate apoptotic cell death (33). Alternatively, IL-2 may be required for the generation of regulatory cells that are essential to contain the alloreactivity to the allografts. In the absence of IL-2 during a critical stage of immune activation, a key regulatory process may not be developed by allograft recipients, and therefore, acquisition of allograft tolerance may prove to be extremely difficult. These possibilities are being actively pursued in the lab.

	Footnotes

 
¹ 1.This work was supported by Grant 1-1999-16 from the Juvenile Diabetes Foundation International (to X.C.L.) and the National Institutes of Health Grants PO1 AI/GF 4152 (to L.A.T. and T.B.S.) and RO1 AI42298 (to T.B.S.).

² X.C.L. and Y.L. contributed equally to this work.

³ Address correspondence and reprint requests to Dr. Terry B. Strom, Department of Medicine, Division of Immunology, Beth Israel Deaconess Medical Center, P.O. Box 15707, RN380, Boston, MA 02215. E-mail address:

⁴ Abbreviations used in this paper: wt, wild-type; KO, knockout; AICD, activation induced cell death; CFSE, 5-carboxyfluorescein diacetate succinimidyl ester; MST, mean survival time.

Received for publication March 12, 1999. Accepted for publication June 14, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Houssaint, E., M. Flajnik. 1990. The role of thymic epithelium in the acquisition of tolerance. Immunol. Today 11:357.[Medline]
2. Ikuta, K., N. Uchida, J. Friedman, I. L. Weissman. 1992. Lymphocyte development from stem cells. Annu. Rev. Immunol. 10:759.[Medline]
3. Sykes, M.. 1996. Chimerism and central tolerance. Curr. Opin. Immunol. 8:694.[Medline]
4. Steiger, J., P. W. Nickerson, W. Steurer, M. Moscovitch-Lopatin, T. B. Strom. 1995. IL-2 knockout recipient mice reject islet cell allografts. J. Immunol. 155:489.[Abstract]
5. Li, X. C., X. X. Zheng, M. S. Zand, Y. Li, T. B. Strom. 1998. IL-2 dependent rapamycin resistant signals are required for tolerance induction and T cell apoptosis. Transplantation 65:S169.
6. Dai, Z., B. T. Konieczny, F. K. Baddoura, F. G. Lakkis. 1998. Impaired alloantigen mediated T cell apoptosis and failure to induce long term allograft survival in IL-2 deficient mice. J. Immunol. 161:1659.[Abstract/Free Full Text]
7. Perez, V. L., L. V. Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.[Medline]
8. Parijs, L. V., A. Ibraghimov, A. K. Abbas. 1996. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4:321.[Medline]
9. Lenardo, M. J.. 1991. Interleukin-2 programs mouse T lymphocytes for apoptosis. Nature 353:858.[Medline]
10. Lau, H. T., M. Yu, A. Fontana, Jr C. J. Stoeckert. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109.[Abstract]
11. Zhang, H., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C. K. Edwards, H. Bluethmann, J. D. Mountz, T. Zhou. 1999. Induction of specific T cell tolerance by Fas ligand expressing antigen presenting cells. J. Immunol. 162:1423.[Abstract/Free Full Text]
12. George, J. F., S. D. Sweeney, J. K. Kirklin, E. M. Simpson, D. R. Goldstein, J. M. Thomas. 1998. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat. Med. 4:333.[Medline]
13. Li, X. C., P. Roy-Chaudhury, W. W. Hancock, R. C. Manfro, M. S. Zand, Y. Li, X. X. Zheng, J. Steiger, P. W. Nickerson, T. R. Malek, T. B. Strom. 1998. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J. Immunol. 161:890.[Abstract/Free Full Text]
14. Larsen, C. P., P. J. Morris, J. M. Austyn. 1990. Migration of dendritic leukocytes from cardiac allografts into host spleens. J. Exp. Med. 171:307.[Abstract/Free Full Text]
15. Tivol, E. A., S. D. Boyd, S. McKeon, F. Borriello, P. W. Nickerson, T. B. Strom, A. H. Sharpe. 1997. CTLA-4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4 deficient mice. J. Immunol. 158:5091.[Abstract]
16. Ishaque, A., M. Al-Rubeai. 1998. Use of intracellular pH and annexin V flow cytometric assays to monitor apoptosis and its suppression by bcl-2 overexpression in hybridoma cell culture. J. Immunol. Methods 221:43.[Medline]
17. Wells, A. D., H. Gudmundsdottir, L. A. Turka. 1997. Following the fate of individual T cells throughout activation and clonal expansion. J. Clin. Invest. 100:3173.[Medline]
18. Song, H. K., H. Noorchashm, Y. K. Lieu, S. Rostami, S. A. S. Greeley, C. F. Barker, A. Naji. 1999. Alloimmune responses against major and minor histocompatibility antigens: distinct division kinetics and requirement for CD28 costimulation. J. Immunol. 162:2467.[Abstract/Free Full Text]
19. Abraham, R. T., G. J. Wiederrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:483.[Medline]
20. Li, Y., X. X. Zheng, X. C. Li, M. S. Zand, T. B. Strom. 1998. Combined costimulation blockade plus rapamycin but not cyclosporine induced permanent cardiac allograft survival. Transplantation 66:1387.[Medline]
21. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn, T. C. Pearson. 1996. Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.[Medline]
22. Nickerson, P. W., X. X. Zheng, J. Steiger, A. W. Steele, W. Steurer, P. Roy-Chaudhury, W. Muller, T. B. Strom. 1996. Prolonged islet allograft acceptance in the absence of interleukin-4 expression. Transplant Immunol. 4:81.[Medline]
23. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature 377:348.[Medline]
24. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, S. Nagata. 1994. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 76:969.[Medline]
25. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.[Medline]
26. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, T. A. Ferguson. 1995. Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270:1189.[Abstract/Free Full Text]
27. Griffith, T. S., X. Yu, J. M. Herndon, D. R. Green, T. A. Ferguson. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5:7.[Medline]
28. Chen, J. J., Y. Sun, G. J. Nabel. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282:1714.[Abstract/Free Full Text]
29. Horak, I., J. Lohler, A. Ma, K. A. Smith. 1995. IL-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol. Rev. 148:35.[Medline]
30. Refaeli, Y., L. V. Parijs, C. A. London, J. Tschopp, A. K. Abbas. 1998. Biochemical mechanisms of IL-2 regulated Fas mediated T cell apoptosis. Immunity 8:615.[Medline]
31. Tschopp, J., M. Irmler, M. Thome. 1998. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 10:552.[Medline]
32. Gutierrez-Ramos, J. C., J. L. Andreu, Y. Revilla, E. Vinuela, C. Martinez-A. 1990. Recovery from autoimmunity of MRL/lpr mice after infection with an IL-2/vaccinia recombinant virus. Nature 346:271.[Medline]
33. Nagata, S.. 1997. Apoptosis by death factor. Cell 88:355.[Medline]

This article has been cited by other articles:

				J.-G. Chai, E. James, H. Dewchand, E. Simpson, and D. Scott Transplantation tolerance induced by intranasal administration of HY peptides Blood, May 15, 2004; 103(10): 3951 - 3959. [Abstract] [Full Text] [PDF]

				E. Sandalova, C.-H. Wei, M. G. Masucci, and V. Levitsky Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering PNAS, March 2, 2004; 101(9): 3011 - 3016. [Abstract] [Full Text] [PDF]

				A. van Maurik, B. F. de St. Groth, K. J. Wood, and N. D. Jones Dependency of Direct Pathway CD4+ T Cells on CD40-CD154 Costimulation Is Determined by Nature and Microenvironment of Primary Contact with Alloantigen J. Immunol., February 15, 2004; 172(4): 2163 - 2170. [Abstract] [Full Text] [PDF]

				A. R. Rao, M. P. Quinones, E. Garavito, Y. Kalkonde, F. Jimenez, C. Gibbons, J. Perez, P. Melby, W. Kuziel, R. L. Reddick, et al. CC Chemokine Receptor 2 Expression in Donor Cells Serves an Essential Role in Graft-versus-Host-Disease J. Immunol., November 1, 2003; 171(9): 4875 - 4885. [Abstract] [Full Text] [PDF]

				G. Demirci, T. B. Strom, and X. C. Li Islet Allograft Rejection in Nonobese Diabetic Mice Involves the Common {gamma}-Chain and CD28/CD154-Dependent and -Independent Mechanisms J. Immunol., October 1, 2003; 171(7): 3878 - 3885. [Abstract] [Full Text] [PDF]

				J. Gonzalez, A. Orlofsky, and M. B. Prystowsky A1 is a growth-permissive antiapoptotic factor mediating postactivation survival in T cells Blood, April 1, 2003; 101(7): 2679 - 2685. [Abstract] [Full Text] [PDF]

				X.-Z. Yu, P. J. Martin, and C. Anasetti CD28 Signal Enhances Apoptosis of CD8 T Cells After Strong TCR Ligation J. Immunol., March 15, 2003; 170(6): 3002 - 3006. [Abstract] [Full Text] [PDF]

				L. Quemeneur, M. Flacher, L.-M. Gerland, M. Ffrench, J.-P. Revillard, and N. Bonnefoy-Berard Mycophenolic Acid Inhibits IL-2-Dependent T Cell Proliferation, But Not IL-2-Dependent Survival and Sensitization to Apoptosis J. Immunol., September 1, 2002; 169(5): 2747 - 2755. [Abstract] [Full Text] [PDF]

				C.-H. Wei, H. Yagita, M. G. Masucci, and V. Levitsky Different Programs of Activation-Induced Cell Death Are Triggered in Mature Activated CTL by Immunogenic and Partially Agonistic Peptide Ligands J. Immunol., January 15, 2001; 166(2): 989 - 995. [Abstract] [Full Text] [PDF]

				P. J. Blair, J. L. Riley, D. M. Harlan, R. Abe, D. K. Tadaki, S. C. Hoffmann, L. White, T. Francomano, S. J. Perfetto, A. D. Kirk, et al. CD40 Ligand (CD154) Triggers a Short-Term CD4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis J. Exp. Med., February 21, 2000; 191(4): 651 - 660. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, X. C. Articles by Strom, T. B. Search for Related Content PubMed PubMed Citation Articles by Li, X. C. Articles by Strom, T. B.